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Abstract
Background: CD40, also called Bp50, is a novel member of the TNF receptor superfamily. Based on its important
role in multiple physiological and pathological processes, the CD40 signaling pathway has become a vital target for
treating transplantation, autoimmune diseases and cancers. This study generated a protein fragment that disrupts
this signaling pathway.
Results: A DNA fragment encoding the extracellular domain of CD40 (CD40-N) has been codon-optimized and
cloned into pPIC9K to create a Pichia pastoris expression and secretion strain. SDS-PAGE and Western blotting
assays using the culture media from methanol-induced expression strains showed that recombinant CD40-N, a
27 kDa glycosylated protein, was secreted into the culture broth. The recombinant protein was purified to more
than 90 % using Sephadex G-50 size-exclusion chromatography and Q Sepharose Fast Flow ion exchange. Finally,
120 mg of the protein was obtained at a relatively high purity from 3 l supernatant. Binding assay (ITC200 assay)
shown the direct interaction of CD40-N and CD40 agonist antibody (G28-5). The bioactivity of recombinant CD40-N
was confirmed by its ability to disrupt non-canonical NF-κB signaling activated by CD40 agonist antibody or CD40
ligand and to inhibit ant-CD40 agonist antibody-induced TNF-alpha expression in BJAB cells in vitro. In addition, our
data indicate that the protein has curative potential in treating dextran sulfate sodium (DSS)-induced colitis in vivo.
Conclusions: The results show that the experimental procedure we have developed using P. pastoris can be used
to produce large amounts of active CD40-N for research and industrial purposes. The protein fragment we have
acquired has potential to be used in research or even treating inflammation diseases such as colitis.
Keywords: CD40, Protein expression and purification, Pichia pastoris, Autoimmune diseases, Colitis
Background
CD40 is a 50-kDa transmembrane protein that belongs
to the TNF receptor family. It is not only expressed on
antigen-presenting cells such as B cells, dendritic cells
and macrophages, but is also found on endothelial cells,
mast cells, fibroblast cells, tumor cells and smooth
muscle cells, suggesting that it has extensive functions in
different physiological contexts [1–4].
There are many downstream signaling pathways
coupled to the CD40 intracellular region, such as Jak3-
stat3, traf6-Erk, p38, JNK, and NF-κB signaling pathway
[5]. Upon binding to CD40 ligand CD40 leads to NF-κB2
p100 processing into p52 and activates non-canonical NF-
κB signaling, this is likely to be important for the tran-
scriptional regulation of CD40 target genes in adaptive
immune responses [6, 7].
During the activation of immune responses, both
TCR-MHC antigen signaling and co-stimulatory signals
such as B7-CD28 are required for antigen-presenting
cells to activate T cells. Activated T cells express high
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level of CD40 ligand that interacts with CD40 on
antigen-presenting cells. In turn CD40-activated non-
canonical NF-κB signaling up-regulates B7 expression
on antigen-presenting cells, thus promoting antigen
presentation [8–11]. In addition to the antigen-
presenting process, CD40-activated signals are also
involved in the priming of T cells [12], the cytotox-
icity of T cells [13], the proliferation and differenti-
ation of B cells, and immunoglobulin class switching
and so on [14]. Although it participates in physio-
logical processes, many studies have been published
on its role in the pathology of disease. Activation of
CD40 signaling is present in type 1 diabetes, multiple
sclerosis (MS), inflammatory bowel disease (IBD), psoria-
sis, rheumatoid arthritis, and systemic lupus erythemato-
sus (SLE) [15]. Disrupting the pathway has shown
significant effects on the treatment of most of these dis-
eases in mouse models (NOD, EAE, IBD, CIA and SLE
mouse models) [16]. Several CD40L-CD40 interaction-
blocking antibodies such as BG9588, IDEC-131 and
ch5D12 have gone through or are undergoing clinical tri-
als, and some have shown curative effects. Thus, the
CD40 signaling pathway is considered to be a promising
target for the clinical treatment of autoimmune diseases
[17–19].
In this study, we aimed to disrupt the CD40L-CD40
interaction by expressing the extracellular domain of
CD40. CD40-N, a 174 amino acids soluble form of
the extracellular domain of CD40, was designed. A
methylotrophic yeast called Pichia pastoris was used
in this study as an efficient protein expression system
to produce large amounts (g/L) of heterologous pro-
tein [20]. The induced protein was secreted into the
culture supernatant and purified by size-exclusion
chromatography and ion exchange chromatography.
Finally, purified CD40-N was obtained with a purity
of more than 90 %. The purified protein was able to
block the CD40 activated signaling in vitro and to de-
crease the symptom of DSS-induced colitis in vivo.
Thus, the purified CD40-N protein may be useful for
further functional and structural studies.
Methods
Mice
Male C57BL/6 mice were purchased from Shanghai
Laboratory Animal Center, Chinese Academy of
Sciences (Shanghai, China). All mice were housed and
maintained in SPF conditions. All animal experiments
were performed in compliance with the Guide for the
Care and Use of Laboratory Animals and approved by
the Institutional Biomedical Research Ethics Commit-
tee of the Shanghai Institutes for Biological Sciences,
Chinese Academy of Sciences.
Strains, plasmids
The cell strain GS115 and the reconstructed plasmid
pPIC9K were provided by the Key Laboratory of Molecu-
lar Medicine of Fudan University [21]. The E. coli strain
DH5α was purchased from TIANGEN Biotech Co., Ltd
(Beijing), and pcDNA3.3 was purchased from Invitrogen.
Yeast nitrogen base (with or without ammonium sul-
fate) was obtained from Sigma. Other reagents were of
analytical purity. Sephadex G-50, and Q-Sepharose-FF
were purchased from GE Healthcare.
Construction of expression vector pPIC9K/CD40-N
CD40-N is the region from 61 bp to 579 bp in CD40
(NM_001250.4), encoding amino acids 21 to 193. A
codon-optimized version of CD40-N was synthesized
with XhoI and NotI sites at either end and cloned into
the pUC57 plasmid by Sangon Biotech. The plasmid was
digested with XhoI and NotI (Thermo Scientific) to re-
lease the CD40-N sequence. The sequence was then
inserted into the yeast expression vector pPIC9K using
the same restriction sites. The ligation product was
transformed into E. coli DH5α competent cells. Success-
ful recombinant colonies with pPIC9k/CD40-N were
confirmed by restriction digest with XhoI and NotI and
sequencing. Small-scale plasmid preparations, restriction
digests, ligations and transformations were performed
according to the manufacturer’s protocols.
Transformation of P. pastoris to produce a CD40-N-
expressing strain
The constructed plasmid pPIC9K/CD40-N was linear-
ized with SalI. The digested product was purified using
an EasyPure PCR Purification Kit (Transgene Biotech)
and used to transform the yeast host strain GS115. The
transformation was carried out by electroporating P.
pastoris as described in the Pichia expression manual
(Invitrogen). Briefly, the GS115 cells were cultured in
YPD medium until the OD600 reached 0.6–0.8. Then,
the cells were pelleted by centrifugation at 3000 rpm for
5 min. Competent cells were generated by washing the
cells twice with ice–cold water and followed by washing
twice with ice-cold D-sorbitol buffer (1 M). Finally, the
competent cells were resuspended in 1 mL of D-sorbitol
buffer mixed with linearized plasmid in an electroporation
cuvette on ice before electroporation (Micropulser™ Bio-
Rad). Transformed cells were supplied with 1 mL ice-cold
D-sorbitol immediately after electroporation and cultured
at 30 °C for 1 h. The transformants were plated on MD
plates (2 % glucose, 4 × 10−5 % biotin, and 1.34 % YNB)
for 2–3 days.
Approximately 800 colonies on the MD plate were
selected and screened for G418 (Amresco E859-5G)
resistance. First, colonies were synchronized twice by
culturing in 200 μL YPD medium in a 96-well plate for
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24 h. Then, colonies were screened in media containing
1 mg/mL G418 for 24 h. Positive colonies (those that
grew on the G418 plate) were cultured in a new plate
with medium containing a higher concentration of G418
(2 mg/mL) for 24 h. This procedure was repeated until
the strain could not grow on the plate. Strains that could
grow at the highest concentration of G418 were stored
at −80 °C for further experiments.
To induce the expression of CD40-N, each clone was
streaked onto an YPD plate to obtain single colony. The
single colony was then inoculated in 50 mL of BMGY in
250 mL flasks and cultured at 30 °C with 220 rpm shak-
ing. When the OD600 reached 3–4, cells were harvested
by centrifugation and briefly rinsed with water to re-
move trace glycerol. Rinsed cells were centrifuged and
re-suspended in 50 mL BMMY. The cells were cultured
in a new 250-mL flask at 30 °C with 220 rpm shaking
and supplemented with methanol to a final concentra-
tion of 1 % every 24 h. 80 μL supernatant sample was
collected every 24 h to examine the expression of CD40-
N by SDS-PAGE and Western blotting.
Large-scale production of CD40-N
Large-scale production of CD40-N was carried out
using the clone that had the best yield in the small-
scale experiments. A single colony was selected and
grown in 5 mL of YPD medium at 30 °C with
220 rpm shaking overnight. The overnight culture
was diluted (1:40) into 200 mL YPD medium and
grown at 30 °C, 220 rpm shaking until an OD600 of
4.0 was reached. The culture was transferred into 3 L
of medium in a bioreactor (Bioflow 3000 NBS) and
grown in batch mode for 20 h. A sharp increase in
dissolved oxygen (DO) occurred when the OD600
reached 70, suggesting that the glycerol was exhausted.
Glycerol (50 %, v/v) was fed at a rate of 20 mL/(L · h) until
the OD600 reached 110. The methanol-fed phase began
once all of the glycerol was consumed. The methanol feed
rate gradually increased from 0.8 to 4 mL/(L · h) in the
first 6 h, allowing the culture to adapt to methanol con-
sumption. After 6 h, the methanol feed rate was main-
tained at 4 mL/L.h for an additional 30 h.
The fermentation medium (1 L) contained 1.5 g
sodium citrate•2H20, 1.01 g CaSO4•2H20, 18 g K2SO4,
7.32 g MgSO4, 4.13 g KOH, 27 mL 85 % H3PO4, 32 mL
glycerin and 2 mL PTM1 solution. A PTM1 solution
was added to the fermentation medium with 2 mL/L.
The PTM1 (1 L) solution contained 6 g CuSO4•5H2O,
3 g MnSO4•H2O, 0.02 g H3BO4, 20 g ZnCl2, 0.8 g KI,
0.2 g NaMoO4•2H2O, 0.49 g CoCl2•6H2O, 65.06 g FeS-
O4•7H2O, 10 mL H2SO4, 0.5 g CaSO4•2H2O, 1.71 g
MgSO4, and 0.2 g biotin, and the solution was sterilized
with a 0.22 μm filter (Merck Millipore MPGL04001).
Purification of the CD40-N protein
The supernatant from the fermentation was loaded
into an ultra-filtration system (Merck Millipore,
P2B005A05) to concentrate it to approximately
500 mL. Then, the sample was run through a Sepha-
dex G-50 size-exclusion column that had been pre-
equilibrated with at least 2 CV (column volumes)
of buffer A (20 mM Tris-HCl, pH 7.4). Then, the
fraction containing the protein was applied to a
Q-Sepharose-FF (2 cm × 50 cm) column at 5 mL/min
using an ÄKTA explorer 100. The column was
washed with buffer A until the UV 280 (nm) was at
the base level. Then, a linear gradient of buffer B
(1.0 mol/L NaCl, 20 mM Tris-HCl pH 7.4) was used
to elute the protein from the column. The protein
concentration was measured by the BCA assay. The
protein sample was lyophilized and stored at −80 °C.
Coomassie blue staining and western blots
SDS-PAGE analysis was performed using 12 % gels
according to the standard method. The entire gel was
stained in Coomassie blue staining solution overnight
before being placed in destaining buffer. For Western
blotting, the proteins on the gel were transferred to a
polyvinylidene difluoride membrane (Immobilon P,
Millipore) using a wet electroblotting apparatus
(Bio-Rad) at 100 V for 50 min in a solution of Tris-
glycine (25 mM Tris, 192 mM glycine). The mem-
brane was blocked by incubating with 5 % non-fat
milk for 1 h at RT. Then, the membrane was immu-
noblotted with primary antibody at 4 °C overnight
and with HRP-conjugated secondary antibodies for
1 h at RT. Detection of the bound antibody was per-
formed using Super Signal West Pico Chemilumines-
cent Substrate (Pierce). The primary antibody against
CD40-N (AF632) was purchased from R&D Systems.
The anti-Flag antibody was purchased from Sigma
(F3165). Mouse monoclonal antibodies against CD40
(G28-5 and 3A8) were purchased from ATCC. Anti–
NF-κB2 (#4882) was purchased from Cell Signaling
Technology (Danvers, MA). Anti–glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) monoclonal antibody
was purchased from Kangchen (KC-5G4, Shanghai,
China).
Sugar content analysis of the recombinant protein
Purified CD40-N was treated with PNGase F (New
England Biolabs P0704S) according to the manufac-
turer’s protocol, and the treated protein was analyzed
by SDS-PAGE.
ITC200 protein protein interaction assay
The cell is filled with G28-5 at 1 mg/mL, and the syringe
is filled with CD40-N at 6 mg/mL. At special time
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intervals (150 s), a small volume (2 μL) of the CD40-N
solution is injected into the cell triggering the binding
reaction and producing the characteristic peak sequence
in the recorded signal (Fig. 6a), during time of each drop
was 4 s, and 19 drops were injected.
Biological activity assay
BJAB cells were plated at a density of 106 cells/mL and
cultured in RPMI 1640 medium supplemented with
10 % FBS and 2-mercaptoethanol (Invitrogen) in 12-well
plates. CD40-N was added at different concentrations of
0, 100, 300, 500 μg/mL at the same time with G28-5
(10 μg/mL). 1 h later, cells were harvested and qRT-PCR
was performed to detect the RNA levels of Bcl-xL and
TNF-alpha. CD40L was purchased from Peprotech
(310–02).
RNA extraction and Real-time polymerase chain reaction
Total RNA was isolated from cell lines using Superfec-
TRITM, Total RNA Isolation Reagent (Shanghai Pufei Bio-
tech Co., Ltd, 3101–100) according to the manufacturer’s
protocol. To obtain cDNA, reverse transcript was per-
formed using PrimeScriptTM RT reagent Kit with gDNA
Eraser (TaKaRa, RR047A) according to the manufacturer’s
instructions and 400 ng RNA was used as template. Quan-
titative real-time PCR (qRT-PCR) were performed using a
7500 Fast Realtime PCR System (Applied Biosystems,
Carlsbad, CA), and all qRT-PCR reagents and consumables
were purchased from Applied Biosystems and TaKaRa. For
each reaction, reverse transcript product was diluted 10
times and 5 μL of the products was added to a 20 μL reac-
tion system (TaKaRa, RR420A). Other reagents including
predesigned and synthesized forward and reverse primer
were added according to the manufacturer’s protocol and a
two steps method was performed. Each sample was ana-
lyzed in triple replication. Relative quantification (RQ) was
derived from the difference in cycle threshold (Ct) between
target gene and actin (△Ct) using the equation RQ= 2-△Ct.
The levels of mRNA were quantitatively assessed by SYBR
Green-based quantitative PCR with gene specific primers.
Actin was used as control. The primers were as follow:
human ACTIN forward primer
CTGGAACGGTGAAGGTGACA,
human ACTIN reverse primer
AAGGGACTTCCTGTAACAATGCA;
human Bcl-xL forward primer
CTGCTGCATTGTTCCCATAG,
human Bcl-xL reverse primer
GACGAGTTTGAACTGCGGTA;
human TNF-alpha forward primer
CAGAGGGAAGAGTTCCCCAG
human TNF-alpha reverse primer
CCTTGGTCTGGTAGGAGACG.
Error bars represent SD, and statistical significance
calculated using two-tailed, unpaired t test.
DSS-induced colitis
Male C57BL/6 mice were fed for 5 days with drinking
water containing dextran sulfate sodium (DSS) (M.W.
36000–50000 Da; MP Biomedical, #160110) at a concen-
tration of 2.75 % (w/v), and then allowed to recover by
drinking regular water for another 2 days. The animals
were weighted daily and monitored for signs of rectal
bleeding.
Results
Construction, expression, and detection of CD40-N
The DNA fragment encoding the partial human CD40 gene
(21–193 aa), CD40-N, underwent codon optimization ac-
cording to yeast’s preference and was inserted between the
XhoI and NotI sites of the expression vector pPIC9K. The
correct sequence of the recombinant was confirmed by
DNA sequencing.
Transformation of P. pastoris with pPIC9K yielded 4
transformants that were able to grow in the presence of
a high concentration of geneticin, including three strains
that grew in 4 mg/mL geneticin on YPD plates and one
strain that grew in 1 mg/mL geneticin. After methanol
induction, the supernatants were harvested and analyzed
by Coomassie blue staining and Western blotting.
Coomassie blue staining detected an increasing band
at approximately 27 kDa that peaked at 96 h, suggest-
ing that CD40-N may be secreted into the culture
medium (the theoretical size of CD40-N is 19.3 kDa;
Fig. 1a). Western blots were performed after CD40-
specific antibody (AF632) was checked. A human
CD40-N (not undergoing codon optimization, with or
without signal sequence) gene fragment was cloned into
pcDNA3.3 plasmid with a Flag tag at the C-terminus. The
constructs were transferred to HEK293T cells and
expressed for the Western blot assay. The CD40 antibody
detected the same band with the Flag antibody, demon-
strating the specificity of the antibody (Fig. 1b). The anti-
body was used to detect the culture medium, and
Western blotting results showed that the potential CD40-
N band in Coomassie blue staining was specifically recog-
nized by the CD40-specific antibody, indicating that the
protein expressed by P. pastoris was recombinant CD40-
N (Fig. 1c). Comparing the band intensities of different
clones by Coomassie blue staining and Western blot ana-
lysis showed that clone number 1 had the highest expres-
sion level of CD40-N.
Fermentation and purification of CD40-N
P. pastoris clone NO.1 was grown in a 5 l stirred bio-
reactor, as described in the Methods section, growth
curve of the yeast was shown in Fig. 2a the amounts of
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expression of CD40-N was peaked at 36 h and then be
kept stable (Fig. 2b). After 36 h of fermentation, the
supernatant, approximately 3 l, was concentrated to ap-
proximately 500 mL after ultrafiltration using a 5 kDa
membrane. Then, the 500 mL sample was applied to a
flow-through Sephadex G50 size-exclusion column to be
desalted and purified from smaller proteins. After that,
ion-exchange chromatography was used to obtain high-
purity protein. A total of 120 mg protein with a purity of
more than 90 % was collected at the washing step using
approximately 0.03 M NaCl in buffer Tris-HCl (pH 7.4)
[22] (Fig. 3).
Sugar content of the recombinant protein
To study the glycosylation of the purified CD40-N, the
purified protein was treated with the deglycosylating
enzyme PNGase F, which is derived from Flavobacter-
ium meningosepticum and can remove N-linked carbo-
hydrates. As shown in Fig. 4, Coomassie blue staining
detected a single band at a molecular weight of 27 kDa
before deglycosylation and a band of approximately
19.3 kDa after treatment. This indicates that the purified
CD40-N was N-glycosylated. The band at approximately
35 kDa was PNGase F [23].
ITC assay proved the interaction of CD40-N and G28-5
To study whether G28-5, a CD40 agonist antibody, can
bind CD40-N directly. We use ITC200 system to analysis
the interaction [24]. The process was performed according
to the method. After saturating the macromolecule, the
residue heat effects are due to mechanical and dilution
effects (Fig. 5a). After the integration of the area of each
Fig. 1 SDS–PAGE and Western blot analysis of recombinant CD40-N expressed in P. pastoris. a A 20-μL sample of supernatant was loaded onto a 12 %
SDS–PAGE gel and stained with Coomassie brilliant blue G-250. All of the SDS-PAGE experiments were performed under the same conditions. Samples
were collected at 12-h intervals for 84 h. The sizes of molecular weight markers (kDa) are shown (M), and recombinant CD40-N protein is indicated with
an arrow. b Western blot analysis of human Flag-tagged CD40-N (not undergoing codon optimization) and CD40-N-S (with signal sequence and not
undergoing codon optimization) expressed in HEK293T cells. pCDNA3.3-CD40-N and pCDNA3.3-CD40-N-S were introduced into HEK293T cells, and the
cell lysates were harvested after 48 h. A 10-μl sample was loaded onto a 12 % SDS–PAGE gel. Anti-Flag, anti-CD40-N and anti-GAPDH antibodies were
used to detect the proteins. c Western blot analysis of proteins at different times in P. pastoris (0, 12, 24, 36, 48, 60, 72, and 84 h). P indicates the positive
control (CD40-N expressed in HEK293T cells)
Fig. 2 Fermentation of the CD40-N-expressing strain. a Growth curve of the Pichia culture. b Time course of CD40-N expression in the bioreactor.
Fermentation supernatants were collected at the indicated times after methanol induction, and recombinant CD40-N protein is indicated with an arrow
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peak, the individual heats are plotted against the molar
ratio from which through nonlinear regression (Fig. 5b), the
thermodynamic parameters was calculated, KD =0.546 μmol,
and △H=−23.24KJ/mol.
CD40-N can disrupt CD40-activated signaling
The recognition of CD40 by CD40 ligand or CD40-
spcific agonist antibody results in NFκB p100 processing
into NFκB p52, activates alternative NFκB signaling and
induces downstream target gene expression. To deter-
mine whether the purified protein CD40-N can disrupt
the interaction of CD40 with CD40L or CD40-specific
agonist antibody, we treated BJAB cells with CD40L in
the presence of titrated CD40N. Western Blot showed
that CD40-N reduced the p100 processing into p52 in-
duced by CD40L in BJAB cells in a dose-dependent
manner (Fig. 6a). G28-5 can activate CD40 signaling and
further induce the expression of downstream target
genes such as TNF-alpha. We observed that CD40-N
significantly reduced TNF-alpha mRNA level induced by
CD40-specific agonist antibody, G28-5, in a dose dependent
manner (Fig. 6b), while the RNA levels of Bcl-xL was not
induced by G28-5 as negative control. These data demon-
strate that the purified protein CD40-N could disrupt the
interaction of CD40 with CD40L or CD40-specific agonist
antibody in vitro.
Functional CD40-N can relieve the symptoms of DSS-induced
colitis
CD40 signaling has been shown to play an important
role in inflammations such as colitis [25–28]. To deter-
mine whether CD40-N functions in vivo, we employed a
Fig. 3 Purification of CD40-N. 1: Marker; 2: sample after purification
Fig. 4 Glycosylation analysis of CD40-N. M: sizes of molecular weight
markers (kDa); PNGase F, treatment of the protein with PNGase F; Con,
treatment of the protein without PNGaseF
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DSS-induced colitis mouse model to test it. At 7-day
post-treatment, the mean body weight of the PBS treated
mice was reduced to 76.8 % of the starting weight; while
the CD40-N treatment could significantly recover the
loss of body weight (88.4 %, Fig. 7a). H&E staining indi-
cated that damage to the architecture of the colon in
CD40-N treatment mice was reduced compared to that
of the control mice, and crypt atrophy and cilia damage
were both less prevalent (Fig. 7b). These data reveal that
CD40-N reduced inflammation in vivo to alleviate the
symptoms of DSS-induced colitis in mice.
Discussion
Targeting CD40L-CD40 interaction could be useful in
clinical applications for curing autoimmune diseases, pro-
viding treatment following transplantation and treating tu-
mors [15]. One strategy to disrupt this interaction is to
use an anti-CD40L monoclonal antibody: this approach
has been shown to be effective in mouse models of RA,
SLE, MS, IBD, T1 diabetes, and inflammatory heart dis-
ease [29]. The humanized CD40L monoclonal antibody
BG9588 (hu5c8) has shown therapeutic effects on SLE pa-
tients in clinical trials [17, 30]. Another humanized mono-
clonal antibody, IDEC-131, was tested in a phase II
clinical study in ITP patients [31]. However, they were not
approved for clinical use because of thrombotic complica-
tions when BG9588 was used in some SLE patients and
IDEC-131 was used in treating Crohn’s disease [27]. A
third humanized anti-CD40L antibody, ABI793, targeted a
different epitope and was found to have the same throm-
botic complications, suggesting that these complications
are a common effect of anti-CD40L antibodies regardless
of epitope specificity. Recently, researchers have found
that the interaction of the Fc fragment of the anti-CD40L
antibody with the Fc receptor CD32 in platelets may cause
platelet cross-linking and lead to clotting [32]. This is
Fig. 5 ITC assay reveals the interaction of CD40-N with CD40-specific
antibody, G28-5. a The heat effects of CD40-N and G28-5; b After
integration of area under each peak (and normalization per mol of
injected protein), the thermodynamic parameters was calculated
using nonlinear regression analysis
Fig. 6 CD40-N disrupts the interaction of CD40 and CD40L or CD40-specific agonist antibody in vitro. a BJAB cells were stimulated with CD40L at
24 h in the presence of titrated purified CD40-N protein (0, 0.1, 1, 10 μg/mL). Western blot was performed to examine p100 procession into
p52. b BJAB cells were stimulated with G28-5 (10 μg/mL) for 1 h with or without CD40-N. Real-time PCR was performed to examine the
gene expression
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consistent with the fact that thrombus formation was not
observed in mouse models because mouse platelets do
not express a homolog of CD32. Reconstruction of the Fc
fragment of the antibody had been shown to eliminate the
complications while maintaining the therapeutic effects of
the anti-CD40L antibody in SLE and MS mouse models
[33, 34]. The transformed isotype of high-affinity fragment
Fab’ and F(ab)’2 has also been studied. All of these
methods provide new insights into the effects of disrupt-
ing CD40L-CD40 interaction using a CD40L antibody.
Another strategy to disrupt this interaction is to target
CD40. Some CD40 antibodies have been tested. HCD122,
an antibody that can disrupt CD40L-CD40 interaction but
cannot activate CD40 signaling, has been used in a clinical
trial to treat CD40+ multiple myeloma because of its
ADCC function [35]. Another antibody, ch5D12, has
shown some curative effect in a phase II clinical study for
the treatment of Crohn’s disease [19].
Targeting the CD40L-CD40 interaction is an import-
ant method of immunotherapy for cancer treatment.
Dacetuzumab (or SGN-40, an anti-CD40 antibody) has
been used in clinical trials for treating CLL, MM and
NHL [36, 37].
Given the importance of the pathway activated by
CD40 in research and its clinical applications, we con-
structed a CD40-N expression system in P. pastoris. P.
pastoris was chosen because of its high production yield,
expression stability, ability to secrete proteins, moderate
post-translational modifications, and simple economical
culture conditions. Additionally, this expression system
has been used to prepare many recombinant proteins for
research and clinical applications [20, 38].
Recombinant CD40-N was purified from the culture
medium by a combination of Sephadex G-50 size-exclusion
and Q FF–Sepharose ion exchange chromatography.
The purity of the final recombinant CD40-N exceeded
90 %. ITC assay verified the interaction of CD40-N with
CD40-specific antibody. The purified CD40-N showed
biologically activity based on its ability to reduce
CD40L-activated non-canonical NF-κB signaling path-
way and inhibit TNF-alpha expression induced by
CD40-specific agonist antibody in a dose-dependent
manner in vitro. Importantly, CD40-N protein could
significantly decrease the inflammation in DSS-induced
colitis mouse model. These data reveal that we have
established a reliable method for the expression and
purification of CD40-N, which is functional in vitro and
in vivo in interrupting the interaction of CD40 and
CD40L.
Because CD40 is a glycoprotein, glycosylation may play
a critical role in its structure and function. We showed
that our recombinant CD40-N was glycosylated with N-
linked sugars, which was responsible for the increased
molecular weight observed by SDS-PAGE (from 19.3 to
27 kDa). The predicted potential N-linked glycosylation
sites of CD40-N are Asn153 and Asn180, and the exact
N-linked sugars sites remain to be elucidated.
Conclusions
This work has successfully generated CD40-N recombin-
ant protein in Pichia pastoris that can disrupt the CD40L-
CD40 interaction. It may serve as a foundation for further
scientific and clinical research. The protein fragment we
have acquired has potential to be used in research or even
treating inflammation diseases such as colitis.
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